Small Volume Injectable Comprehensive Study by Application (Local Anesthetics, Vaccines, Others), End Use (Hospitals, Healthcare Systems, Ambulatory Care Infusion Centers), Package (Ampules, Vials, Prefilled Syringes) Players and Region - Global Market Outlook to 2030

Small Volume Injectable Market by XX Submarkets | Forecast Years 2024-2030  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Small Volume Injectable
Injectables or small-volume parenteral solutions (SVPs) are solutions having a volume of less than 100 mL (as specified by USP) that are designed for intermittent intravenous delivery (usually defined as an infusion time not lasting longer than 6-8 hours). Powdered medications are packaged in vials and must be constituted (dissolved in a suitable liquid) before being used in a solution. SVPs in the form of ampules, vials, or prefilled syringes are usually added to a minibag or an LVP, but they can also be used as the final container. A solution to which such an additive has been added to a minibag or LVP is referred to as an admixture. SVPs are the backbone of basic IV compounding for hundreds of medicines that require additional dilution. Hospitals, healthcare systems, and ambulatory care infusion facilities continue to experience intermittent shortages of small-volume parenteral solutions (SVPs).

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States & German Players will contribute the maximum growth to Global Small Volume Injectable market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan Inc. (Ireland), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Bayer AG (Germany), Teva Pharmaceuticals (Israel), Pfizer Inc. (United States), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland) and Baxter International, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), B. Braun Melsungen (Germany) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Small Volume Injectable market by , Application (Local Anesthetics, Vaccines and Others) and Region.



On the basis of geography, the market of Small Volume Injectable has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Small Volume Injectable market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Package, the sub-segment i.e. Ampules will boost the Small Volume Injectable market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Prevalence of Chronic Infectious Diseases and High Investment in Health Care R&D

Challenges:
Fierce Competitive Pressure

Restraints:
Lack of Skilled Professionals and High Initial Investment

Opportunities:
Growing Healthcare Infrastructure Across Emerging Regions

Market Leaders and their expansionary development strategies
In May 2021, Dr. Reddy's Laboratories Launched Ertapenem for Injection in the U.S. Market. The New Injection, 1 g/vial, is a Therapeutically Equivalent Generic Version of INVANZ (Ertapenem for Injection), 1 G/Vial, Approved by The US Food and Drug Administration (USFDA).
In May 2020, Tolmar Pharmaceuticals, Inc Received U.S. Food and Drug Administration (FDA) Approval to its New Drug Application for FENSOLVI (leuprolide acetate) For Injectable Suspension for The Treatment of Pediatric Patients Two Years of Age and Older with Central Precocious Puberty (CPP).


Key Target Audience
Small Volume Injectable Manufactures, New Entrants and Investors, Small Volume Injectable Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Local Anesthetics
  • Vaccines
  • Others
By End Use
  • Hospitals
  • Healthcare Systems
  • Ambulatory Care Infusion Centers

By Package
  • Ampules
  • Vials
  • Prefilled Syringes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Chronic Infectious Diseases
      • 3.2.2. High Investment in Health Care R&D
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Small Volume Injectable, by Application, End Use, Package and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Small Volume Injectable (Value)
      • 5.2.1. Global Small Volume Injectable by: Application (Value)
        • 5.2.1.1. Local Anesthetics
        • 5.2.1.2. Vaccines
        • 5.2.1.3. Others
      • 5.2.2. Global Small Volume Injectable by: End Use (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Healthcare Systems
        • 5.2.2.3. Ambulatory Care Infusion Centers
      • 5.2.3. Global Small Volume Injectable by: Package (Value)
        • 5.2.3.1. Ampules
        • 5.2.3.2. Vials
        • 5.2.3.3. Prefilled Syringes
      • 5.2.4. Global Small Volume Injectable Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Small Volume Injectable: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Inc. (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Becton, Dickinson and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Baxter International, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Small Volume Injectable Sale, by Application, End Use, Package and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Small Volume Injectable (Value)
      • 7.2.1. Global Small Volume Injectable by: Application (Value)
        • 7.2.1.1. Local Anesthetics
        • 7.2.1.2. Vaccines
        • 7.2.1.3. Others
      • 7.2.2. Global Small Volume Injectable by: End Use (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Healthcare Systems
        • 7.2.2.3. Ambulatory Care Infusion Centers
      • 7.2.3. Global Small Volume Injectable by: Package (Value)
        • 7.2.3.1. Ampules
        • 7.2.3.2. Vials
        • 7.2.3.3. Prefilled Syringes
      • 7.2.4. Global Small Volume Injectable Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Small Volume Injectable: by Application(USD Million)
  • Table 2. Small Volume Injectable Local Anesthetics , by Region USD Million (2018-2023)
  • Table 3. Small Volume Injectable Vaccines , by Region USD Million (2018-2023)
  • Table 4. Small Volume Injectable Others , by Region USD Million (2018-2023)
  • Table 5. Small Volume Injectable: by End Use(USD Million)
  • Table 6. Small Volume Injectable Hospitals , by Region USD Million (2018-2023)
  • Table 7. Small Volume Injectable Healthcare Systems , by Region USD Million (2018-2023)
  • Table 8. Small Volume Injectable Ambulatory Care Infusion Centers , by Region USD Million (2018-2023)
  • Table 9. Small Volume Injectable: by Package(USD Million)
  • Table 10. Small Volume Injectable Ampules , by Region USD Million (2018-2023)
  • Table 11. Small Volume Injectable Vials , by Region USD Million (2018-2023)
  • Table 12. Small Volume Injectable Prefilled Syringes , by Region USD Million (2018-2023)
  • Table 13. South America Small Volume Injectable, by Country USD Million (2018-2023)
  • Table 14. South America Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 15. South America Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 16. South America Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 17. Brazil Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 18. Brazil Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 19. Brazil Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 20. Argentina Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 21. Argentina Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 22. Argentina Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 23. Rest of South America Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 25. Rest of South America Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 26. Asia Pacific Small Volume Injectable, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 29. Asia Pacific Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 30. China Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 31. China Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 32. China Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 33. Japan Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 34. Japan Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 35. Japan Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 36. India Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 37. India Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 38. India Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 39. South Korea Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 40. South Korea Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 41. South Korea Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 42. Taiwan Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 43. Taiwan Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 44. Taiwan Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 45. Australia Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 46. Australia Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 47. Australia Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 51. Europe Small Volume Injectable, by Country USD Million (2018-2023)
  • Table 52. Europe Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 53. Europe Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 54. Europe Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 55. Germany Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 56. Germany Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 57. Germany Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 58. France Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 59. France Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 60. France Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 61. Italy Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 62. Italy Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 63. Italy Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 64. United Kingdom Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 66. United Kingdom Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 67. Netherlands Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 68. Netherlands Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 69. Netherlands Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 70. Rest of Europe Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 72. Rest of Europe Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 73. MEA Small Volume Injectable, by Country USD Million (2018-2023)
  • Table 74. MEA Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 75. MEA Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 76. MEA Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 77. Middle East Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 78. Middle East Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 79. Middle East Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 80. Africa Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 81. Africa Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 82. Africa Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 83. North America Small Volume Injectable, by Country USD Million (2018-2023)
  • Table 84. North America Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 85. North America Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 86. North America Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 87. United States Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 88. United States Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 89. United States Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 90. Canada Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 91. Canada Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 92. Canada Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 93. Mexico Small Volume Injectable, by Application USD Million (2018-2023)
  • Table 94. Mexico Small Volume Injectable, by End Use USD Million (2018-2023)
  • Table 95. Mexico Small Volume Injectable, by Package USD Million (2018-2023)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Small Volume Injectable: by Application(USD Million)
  • Table 107. Small Volume Injectable Local Anesthetics , by Region USD Million (2025-2030)
  • Table 108. Small Volume Injectable Vaccines , by Region USD Million (2025-2030)
  • Table 109. Small Volume Injectable Others , by Region USD Million (2025-2030)
  • Table 110. Small Volume Injectable: by End Use(USD Million)
  • Table 111. Small Volume Injectable Hospitals , by Region USD Million (2025-2030)
  • Table 112. Small Volume Injectable Healthcare Systems , by Region USD Million (2025-2030)
  • Table 113. Small Volume Injectable Ambulatory Care Infusion Centers , by Region USD Million (2025-2030)
  • Table 114. Small Volume Injectable: by Package(USD Million)
  • Table 115. Small Volume Injectable Ampules , by Region USD Million (2025-2030)
  • Table 116. Small Volume Injectable Vials , by Region USD Million (2025-2030)
  • Table 117. Small Volume Injectable Prefilled Syringes , by Region USD Million (2025-2030)
  • Table 118. South America Small Volume Injectable, by Country USD Million (2025-2030)
  • Table 119. South America Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 120. South America Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 121. South America Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 122. Brazil Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 123. Brazil Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 124. Brazil Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 125. Argentina Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 126. Argentina Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 127. Argentina Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 128. Rest of South America Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 129. Rest of South America Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 130. Rest of South America Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 131. Asia Pacific Small Volume Injectable, by Country USD Million (2025-2030)
  • Table 132. Asia Pacific Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 133. Asia Pacific Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 134. Asia Pacific Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 135. China Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 136. China Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 137. China Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 138. Japan Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 139. Japan Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 140. Japan Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 141. India Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 142. India Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 143. India Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 144. South Korea Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 145. South Korea Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 146. South Korea Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 147. Taiwan Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 148. Taiwan Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 149. Taiwan Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 150. Australia Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 151. Australia Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 152. Australia Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 156. Europe Small Volume Injectable, by Country USD Million (2025-2030)
  • Table 157. Europe Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 158. Europe Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 159. Europe Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 160. Germany Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 161. Germany Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 162. Germany Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 163. France Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 164. France Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 165. France Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 166. Italy Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 167. Italy Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 168. Italy Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 169. United Kingdom Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 170. United Kingdom Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 171. United Kingdom Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 172. Netherlands Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 173. Netherlands Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 174. Netherlands Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 175. Rest of Europe Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 176. Rest of Europe Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 177. Rest of Europe Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 178. MEA Small Volume Injectable, by Country USD Million (2025-2030)
  • Table 179. MEA Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 180. MEA Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 181. MEA Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 182. Middle East Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 183. Middle East Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 184. Middle East Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 185. Africa Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 186. Africa Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 187. Africa Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 188. North America Small Volume Injectable, by Country USD Million (2025-2030)
  • Table 189. North America Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 190. North America Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 191. North America Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 192. United States Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 193. United States Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 194. United States Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 195. Canada Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 196. Canada Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 197. Canada Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 198. Mexico Small Volume Injectable, by Application USD Million (2025-2030)
  • Table 199. Mexico Small Volume Injectable, by End Use USD Million (2025-2030)
  • Table 200. Mexico Small Volume Injectable, by Package USD Million (2025-2030)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Small Volume Injectable: by Application USD Million (2018-2023)
  • Figure 5. Global Small Volume Injectable: by End Use USD Million (2018-2023)
  • Figure 6. Global Small Volume Injectable: by Package USD Million (2018-2023)
  • Figure 7. South America Small Volume Injectable Share (%), by Country
  • Figure 8. Asia Pacific Small Volume Injectable Share (%), by Country
  • Figure 9. Europe Small Volume Injectable Share (%), by Country
  • Figure 10. MEA Small Volume Injectable Share (%), by Country
  • Figure 11. North America Small Volume Injectable Share (%), by Country
  • Figure 12. Global Small Volume Injectable share by Players 2023 (%)
  • Figure 13. Global Small Volume Injectable share by Players (Top 3) 2023(%)
  • Figure 14. Global Small Volume Injectable share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Allergan Inc. (Ireland) Revenue: by Geography 2023
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 24. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 34. Baxter International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Baxter International, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Small Volume Injectable: by Application USD Million (2025-2030)
  • Figure 37. Global Small Volume Injectable: by End Use USD Million (2025-2030)
  • Figure 38. Global Small Volume Injectable: by Package USD Million (2025-2030)
  • Figure 39. South America Small Volume Injectable Share (%), by Country
  • Figure 40. Asia Pacific Small Volume Injectable Share (%), by Country
  • Figure 41. Europe Small Volume Injectable Share (%), by Country
  • Figure 42. MEA Small Volume Injectable Share (%), by Country
  • Figure 43. North America Small Volume Injectable Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan Inc. (Ireland)
  • GlaxoSmithKline plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Bayer AG (Germany)
  • Teva Pharmaceuticals (Israel)
  • Pfizer Inc. (United States)
  • Becton, Dickinson and Company (United States)
  • Eli Lilly and Company (United States)
  • Novartis AG (Switzerland)
  • Baxter International, Inc. (United States)
Additional players considered in the study are as follows:
Schott AG (Germany) , Gerresheimer (Germany) , Ypsomed (Switzerland) , B. Braun Melsungen (Germany) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 221 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan Inc. (Ireland), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Bayer AG (Germany), Teva Pharmaceuticals (Israel), Pfizer Inc. (United States), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Novartis AG (Switzerland) and Baxter International, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Geriatric Population" is seen as one of major influencing trends for Small Volume Injectable Market during projected period 2023-2030.
The Small Volume Injectable market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Small Volume Injectable Market Report?